Milvexian: Next-Generation Blood Thinner That Prevents Clots Without Bleeding Risk

Why Is Milvexian a Breakthrough in Blood Thinners?

All currently available anticoagulants — warfarin, the direct oral anticoagulants (DOACs: apixaban, rivaroxaban, edoxaban), and heparins — target clotting factors that are essential for both pathological thrombosis and normal hemostasis (wound healing). This means that effective anticoagulation invariably increases bleeding risk, creating a fundamental therapeutic limitation. Approximately 3–4% of patients on DOACs experience major bleeding annually, and the fear of bleeding is the most common reason physicians underdose or withhold anticoagulation in eligible patients.

Factor XI occupies a unique position in the coagulation cascade. Genetic studies have shown that people with natural factor XI deficiency (hemophilia C) have a dramatically lower risk of stroke and venous thromboembolism but rarely experience spontaneous bleeding — only after major surgery or trauma. This observation led to the hypothesis that selectively inhibiting factor XI could prevent pathological clots without impairing wound healing. Milvexian, developed by Bristol-Myers Squibb and Janssen, is a small-molecule oral inhibitor of activated factor XI (factor XIa). Phase 2 dose-finding studies, including the AXIOMATIC-SSP trial published in the New England Journal of Medicine, confirmed that milvexian has a favorable bleeding profile across a range of doses.

What Does the LIBREXIA-AF Trial Aim to Show?

The LIBREXIA-AF trial is a pivotal Phase 3 randomized controlled trial enrolling thousands of patients with atrial fibrillation and moderate-to-high stroke risk. It compares milvexian to apixaban (the DOAC with the most favorable bleeding profile) to evaluate both efficacy in stroke prevention and safety in terms of major bleeding events. The trial is event-driven, meaning it will continue until a sufficient number of clinical endpoints have been reached to determine whether milvexian is non-inferior to apixaban for stroke prevention and superior in reducing bleeding.

The scientific rationale is strong: since factor XIa is involved primarily in the amplification of thrombin generation through the contact pathway rather than in wound-healing hemostasis, inhibiting it should theoretically decouple antithrombotic protection from bleeding risk. However, this promise was challenged in 2023 when Bayer's competing factor XIa inhibitor asundexian failed the OCEANIC-AF trial, which was stopped early for futility after it failed to show non-inferiority to apixaban. This makes LIBREXIA-AF's results critical for validating the entire factor XIa inhibitor class. If milvexian succeeds where asundexian failed, it could transform anticoagulation therapy for the estimated 6 million Americans and over 30 million people worldwide with atrial fibrillation.